Novel putative pharmacological therapies to protect the right ventricle in pulmonary hypertension: a review of current literature
- 24 February 2017
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 174 (7) , 497-511
Abstract
Pulmonary hypertension (PH) is defined by elevated mean pulmonary artery pressure following the pathological remodelling of small pulmonary arteries. An increase in right ventricular (RV) afterload results in RV hypertrophy and RV failure. The pathophysiology of PH, and RV remodelling in particular, is not well understood, thus explaining, at least in part, why current PH therapies have a limited effect. Existing therapies mostly target the pulmonary circulation. Because the remodelled RV fails to support normal cardiac function, patients eventually succumb from RV failure. Developing novel therapies that directly target the function of the RV may therefore benefit patients with PH. In the past decade, several promising studies have investigated novel cardioprotective strategies in experimental models of PH. This review aims to comprehensively discuss and highlight these novel experimental approaches to confer, in the long‐term, greater health benefit in patients with PH.Keywords
Funding Information
- Universityof CapeTown
- South African Medical Research Council
This publication has 141 references indexed in Scilit:
- Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohortHeart, 2012
- Selective Class I Histone Deacetylase Inhibition Suppresses Hypoxia-Induced Cardiopulmonary Remodeling Through an Antiproliferative MechanismCirculation Research, 2012
- Spontaneous Ventricular Fibrillation in Right Ventricular Failure Secondary to Chronic Pulmonary HypertensionCirculation: Arrhythmia and Electrophysiology, 2012
- Resveratrol reverses monocrotaline-induced pulmonary vascular and cardiac dysfunction: A potential role for atrogin-1 in smooth muscleVascular Pharmacology, 2012
- In search of new therapeutic targets and strategies for heart failure: recent advances in basic scienceThe Lancet, 2011
- Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagyProceedings of the National Academy of Sciences, 2011
- The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricleJournal of Molecular Medicine, 2009
- Unique MicroRNA Profile in End-stage Heart Failure Indicates Alterations in Specific Cardiovascular Signaling NetworksJournal of Biological Chemistry, 2009
- Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)European Heart Journal, 2009
- Heme Oxygenase-1 Regulates Cardiac Mitochondrial Biogenesis via Nrf2-Mediated Transcriptional Control of Nuclear Respiratory Factor-1Circulation Research, 2008